A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs ASP-8374 (Primary) ; Pembrolizumab (Primary)
Indications Bladder cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Astellas Pharma Global Development

18 May 2022 Status changed from active, no longer recruiting to completed.
08 Apr 2022 Planned primary completion date changed from 31 Mar 2022 to 30 Apr 2022.
20 Sep 2021 Planned End Date changed from 31 Mar 2022 to 30 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com